KR102826021B1 - Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체 - Google Patents

Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체 Download PDF

Info

Publication number
KR102826021B1
KR102826021B1 KR1020237002074A KR20237002074A KR102826021B1 KR 102826021 B1 KR102826021 B1 KR 102826021B1 KR 1020237002074 A KR1020237002074 A KR 1020237002074A KR 20237002074 A KR20237002074 A KR 20237002074A KR 102826021 B1 KR102826021 B1 KR 102826021B1
Authority
KR
South Korea
Prior art keywords
pyran
methyl
compound
mmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237002074A
Other languages
English (en)
Korean (ko)
Other versions
KR20230019496A (ko
Inventor
벨레 다비드 딘
미코 매켈래
미코 파시니에미
페카 피에티캐이넨
페테리 루마코
에이자 티아이넨
마티 바이스마
게르드 보흘파흐르트
Original Assignee
오리온 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리온 코포레이션 filed Critical 오리온 코포레이션
Priority to KR1020257020993A priority Critical patent/KR20250097993A/ko
Publication of KR20230019496A publication Critical patent/KR20230019496A/ko
Application granted granted Critical
Publication of KR102826021B1 publication Critical patent/KR102826021B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
KR1020237002074A 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체 Active KR102826021B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257020993A KR20250097993A (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FI20166024 2016-12-22
FI20166024 2016-12-22
KR1020197021256A KR102491308B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
PCT/FI2017/050926 WO2018115591A1 (en) 2016-12-22 2017-12-21 Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021256A Division KR102491308B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257020993A Division KR20250097993A (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Publications (2)

Publication Number Publication Date
KR20230019496A KR20230019496A (ko) 2023-02-08
KR102826021B1 true KR102826021B1 (ko) 2025-06-30

Family

ID=61005837

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237002074A Active KR102826021B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR1020257020993A Pending KR20250097993A (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR1020197021256A Active KR102491308B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257020993A Pending KR20250097993A (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR1020197021256A Active KR102491308B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Country Status (30)

Country Link
US (4) US10717726B2 (enExample)
EP (2) EP3558981B1 (enExample)
JP (2) JP7025432B2 (enExample)
KR (3) KR102826021B1 (enExample)
CN (2) CN116162084B (enExample)
AR (1) AR110412A1 (enExample)
AU (2) AU2017380282B2 (enExample)
CA (1) CA3047370A1 (enExample)
CL (1) CL2019001728A1 (enExample)
CO (1) CO2019007321A2 (enExample)
CY (1) CY1124461T1 (enExample)
DK (1) DK3558981T3 (enExample)
EA (1) EA039309B1 (enExample)
ES (1) ES2880151T3 (enExample)
HR (1) HRP20211255T1 (enExample)
HU (1) HUE056540T2 (enExample)
IL (2) IL267484B (enExample)
LT (1) LT3558981T (enExample)
MA (2) MA55983A (enExample)
MX (1) MX388538B (enExample)
PE (1) PE20191137A1 (enExample)
PH (1) PH12019550111A1 (enExample)
PL (1) PL3558981T3 (enExample)
PT (1) PT3558981T (enExample)
RS (1) RS62198B1 (enExample)
SI (1) SI3558981T1 (enExample)
TN (1) TN2019000189A1 (enExample)
TW (2) TWI762544B (enExample)
UA (1) UA124640C2 (enExample)
WO (1) WO2018115591A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
CN115551831A (zh) * 2020-05-14 2022-12-30 奥赖恩公司 Cyp11a1抑制剂
CN116724034B (zh) * 2020-12-01 2026-06-05 奥赖恩公司 作为用于治疗前列腺癌的cyp11a1抑制剂的2,3-二氢-4h-苯并[b][1,4]噁嗪-4-基)(5-(苯基)-吡啶-3-基)甲酮衍生物和类似化合物
CN117279893A (zh) 2021-03-01 2023-12-22 奥仁公司 用于制备cyp11a1抑制剂及其中间体的方法
AR124985A1 (es) 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
CN117242070A (zh) * 2021-03-01 2023-12-15 奥仁公司 4h-吡喃-4-酮结构化cyp11a1抑制剂的固体形式
AU2022297768A1 (en) 2021-06-23 2024-01-18 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
EP4408426A1 (en) * 2021-09-28 2024-08-07 Orion Corporation Cyp11a1 inhibitor for use in the treatment of prostate cancer
WO2023073285A1 (en) 2021-10-28 2023-05-04 Orion Corporation Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor
EP4430027A1 (en) 2021-11-10 2024-09-18 Orion Corporation Cyp11a1 inhibitors
KR20240130101A (ko) 2022-01-20 2024-08-28 오리온 코포레이션 Cyp11a1 억제제의 약제 조성물
CN118307519A (zh) * 2023-01-06 2024-07-09 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
KR20240126916A (ko) 2023-02-14 2024-08-22 경북대학교 산학협력단 Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물
TW202440557A (zh) 2023-03-29 2024-10-16 大陸商西藏海思科製藥有限公司 Cyp11a1抑制劑及其用途
JP2026514915A (ja) 2023-04-21 2026-05-13 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｃｙｐ１１ａ１阻害剤及びその用途
KR20260040160A (ko) * 2023-05-11 2026-03-24 셴젠 이오노바 라이프 사이언스 시오., 엘티디. Cyp11a1 억제제로서의 신규 화합물 및 그 용도
EP4746854A1 (en) 2023-07-19 2026-05-27 Orion Corporation Stable pharmaceutical compositions of a cyp11a1 inhibitor
WO2025021182A1 (en) * 2023-07-27 2025-01-30 Acerand Therapeutics (Hong Kong) Limited Cyp11a1 inhibitors
CN121889383A (zh) * 2023-09-08 2026-04-17 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技（苏州）有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用
TW202613102A (zh) * 2024-05-27 2026-04-01 大陸商遼寧海思科製藥有限公司 Cyp11a1抑制劑的鹽及其晶型、其製備方法和應用
WO2026021515A1 (zh) * 2024-07-25 2026-01-29 海思科制药(眉山)有限公司 一种cyp11a1抑制剂的制备方法
WO2026040949A1 (zh) * 2024-08-19 2026-02-26 辽宁海思科制药有限公司 一种cyp11a1抑制剂的药物组合物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076445A2 (en) 2003-02-28 2004-09-10 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
WO2014202827A1 (en) 2013-06-11 2014-12-24 Orion Corporation Novel cyp17 inhibitors/antiandrogens
KR102491308B1 (ko) * 2016-12-22 2023-01-27 오리온 코포레이션 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176485A (ja) * 1984-09-20 1986-04-18 Ss Pharmaceut Co Ltd 新規なγ−ピラン誘導体
WO2003074450A2 (en) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076445A2 (en) 2003-02-28 2004-09-10 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
WO2014202827A1 (en) 2013-06-11 2014-12-24 Orion Corporation Novel cyp17 inhibitors/antiandrogens
KR102491308B1 (ko) * 2016-12-22 2023-01-27 오리온 코포레이션 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Also Published As

Publication number Publication date
EP3868756A1 (en) 2021-08-25
IL285729B (en) 2022-02-01
MA55983A (fr) 2022-03-23
TWI762544B (zh) 2022-05-01
JP2022078068A (ja) 2022-05-24
TW202229264A (zh) 2022-08-01
AU2021203497A1 (en) 2021-07-01
US20210347765A1 (en) 2021-11-11
MA47102B1 (fr) 2021-09-30
IL267484B (en) 2021-09-30
MX2019007373A (es) 2019-09-18
EA201991513A1 (ru) 2019-11-29
PE20191137A1 (es) 2019-09-02
JP7025432B2 (ja) 2022-02-24
KR20250097993A (ko) 2025-06-30
EP3558981B1 (en) 2021-05-26
CO2019007321A2 (es) 2019-07-31
KR102491308B1 (ko) 2023-01-27
TWI796205B (zh) 2023-03-11
HRP20211255T1 (hr) 2021-11-12
JP7286825B2 (ja) 2023-06-05
TW201835072A (zh) 2018-10-01
AU2017380282A1 (en) 2019-08-01
PL3558981T3 (pl) 2021-12-06
MX388538B (es) 2025-03-20
US11098032B2 (en) 2021-08-24
AU2021203497B2 (en) 2022-11-10
HUE056540T2 (hu) 2022-02-28
KR20190095950A (ko) 2019-08-16
NZ755395A (en) 2025-10-31
LT3558981T (lt) 2021-08-25
US10717726B2 (en) 2020-07-21
WO2018115591A1 (en) 2018-06-28
CN110139861B (zh) 2022-12-30
AU2017380282B2 (en) 2021-06-24
JP2020502229A (ja) 2020-01-23
CA3047370A1 (en) 2018-06-28
CN110139861A (zh) 2019-08-16
PT3558981T (pt) 2021-07-06
PH12019550111A1 (en) 2020-03-09
SI3558981T1 (sl) 2021-09-30
UA124640C2 (uk) 2021-10-20
EP3558981A1 (en) 2019-10-30
CL2019001728A1 (es) 2019-09-27
RS62198B1 (sr) 2021-08-31
IL267484A (en) 2019-08-29
CY1124461T1 (el) 2022-07-22
BR112019012906A2 (pt) 2019-12-03
CN116162084A (zh) 2023-05-26
KR20230019496A (ko) 2023-02-08
ES2880151T3 (es) 2021-11-23
CN116162084B (zh) 2025-12-09
IL285729A (en) 2021-09-30
US12030871B2 (en) 2024-07-09
US20240308989A1 (en) 2024-09-19
DK3558981T3 (da) 2021-07-26
AR110412A1 (es) 2019-03-27
US20190359601A1 (en) 2019-11-28
EA039309B1 (ru) 2022-01-12
US20200299280A1 (en) 2020-09-24
TN2019000189A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
KR102491308B1 (ko) Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
CA3178067A1 (en) Cyp11a1 inhibitors
US20240279210A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
CN101370806A (zh) 取代的4-苯基哌啶
BR122024021737A2 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos
HK40016600A (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
HK40016600B (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
BR112019012906B1 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos
HK40093308A (en) Pyran derivatives as cyp11a1 inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230118

Application number text: 1020197021256

Filing date: 20190719

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230830

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0701 Decision of registration after re-examination

Patent event date: 20250321

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250623

Application number text: 1020197021256

Filing date: 20190719

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250624

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250625

End annual number: 3

Start annual number: 1

PG1601 Publication of registration